Press Release

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

Press Release

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

WASHINGTON--(EON: Enhanced Online News)--American Epilepsy Society Annual Meeting, Booth 1101--NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop…

NeuroPace Inc.December 5, 2017

Press Release

NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World’s First Brain-Responsive Neurostimulation System to Treat Epilepsy

MOUNTAIN VIEW, Calif. – October 24, 2017 – NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive…

NeuroPace Inc.October 23, 2017

Press Release

NeuroPace Announces 1,000th Patient Treated with RNS System for Medically Refractory Epilepsy

MOUNTAIN VIEW, California – February 20, 2017 – NeuroPace, Inc. announced today that the 1000th patient has been treated with its award-winning RNS® System, approved…

NeuroPace Inc.February 27, 2017

Press Release

NeuroPace, Inc. Announces Results of 7 Years of Clinical Trial Follow-up Demonstrating 72 Percent Seizure Reduction with the RNS® System – December 4, 2016

NeuroPace Inc.December 7, 2016

Press Release

FDA Grants Premarket Approval (PMA) for the NeuroPace RNS® System to treat Medically Refractory Epilepsy — November 14, 2013

NeuroPace Inc.November 14, 2013

Archived Press Release Press Release

FDA Advisory Panel Recommends Approval of the NeuroPace RNS® System for Medically Refractory Epilepsy — February 25, 2013

NeuroPace Inc.February 25, 2013

Previous 1 2 3 4 Next

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

Press Release

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World’s First Brain-Responsive Neurostimulation System to Treat Epilepsy

NeuroPace Announces 1,000th Patient Treated with RNS System for Medically Refractory Epilepsy

NeuroPace, Inc. Announces Results of 7 Years of Clinical Trial Follow-up Demonstrating 72 Percent Seizure Reduction with the RNS® System – December 4, 2016

NeuroPace RNS® System Honored With Prestigious Award — November 11, 2015

NeuroPace RNS® System Associated with Positive Effects In Memory and Language — October 20, 2015

Long-term Treatment Study Data Show Sustained Effectiveness in Adults — February 2, 2015

NeuroPace® RNS® System Receives Approval from CMS for New Technology Add-On Payments — August 6, 2014

FDA Grants Premarket Approval (PMA) for the NeuroPace RNS® System to treat Medically Refractory Epilepsy — November 14, 2013

FDA Advisory Panel Recommends Approval of the NeuroPace RNS® System for Medically Refractory Epilepsy — February 25, 2013

PATIENTS

PROVIDERS

ABOUT US

PATIENTS

PROVIDERS

INVESTORS

ABOUT US

Step 1 of 7